Page 293 - Binder2

and taken. They turn the factory into a farm. They turn
dosing into nourishment. They relocate production from
pharma campuses to indoor farms, rural communities, or
even—someday—your backyard.

They make decentralization not a supply chain risk, but a
therapeutic strength.

5.3 – Real Patients, Real Promise: Compassionate
Use and Early Trials

By this point, the concept of edible biologics might feel
elegant in theory. But for patients, theory isn’t enough.
They need something that works. Something they can take
today—not just dream about tomorrow.

And in some cases, they already have.

While large-scale clinical trials are still ramping up, a
growing number of patients have received edible biologics
through early-stage studies, expanded access programs, or
compassionate-use protocols. These aren’t hypothetical
scenarios—they’re lived experiences. They provide a
window into what’s possible when biology, agriculture, and
medicine converge.

This chapter doesn’t just tell you how edible biologics are
made. It shows you why they matter. Because behind every
leaf is a life.

291